Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This randomized controled open label clinical trial is to evaluate the effect of
Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.